Novartis AG ADR (NVS)vsRevvity Inc. (RVTY)
NVS
Novartis AG ADR
$153.67
-0.26%
HEALTHCARE · Cap: $290.96B
RVTY
Revvity Inc.
$111.39
-3.32%
HEALTHCARE · Cap: $12.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1853% more annual revenue ($56.69B vs $2.90B). NVS leads profitability with a 22.5% profit margin vs 8.3%. RVTY appears more attractively valued with a PEG of 0.68. RVTY earns a higher WallStSmart Score of 54/100 (C-).
NVS
Buy51
out of 100
Grade: C-
RVTY
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-70.9%
Fair Value
$92.73
Current Price
$153.67
$60.94 premium
Intrinsic value data unavailable for RVTY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
3.5% earnings growth
ROE of 3.4% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : RVTY
The strongest argument for RVTY centers on PEG Ratio, Price/Book. PEG of 0.68 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : RVTY
The primary concerns for RVTY are EPS Growth, Return on Equity, P/E Ratio. A P/E of 52.1x leaves little room for execution misses.
Key Dynamics to Monitor
RVTY carries more volatility with a beta of 1.09 — expect wider price swings.
RVTY is growing revenue faster at 7.0% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVTY scores higher overall (54/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Revvity Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?